

# Marc G Ghany

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8539396/publications.pdf>

Version: 2024-02-01

193  
papers

20,695  
citations

16791

66  
h-index

11282

141  
g-index

199  
all docs

199  
docs citations

199  
times ranked

17486  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 125-135.e8.	2.4	3
2	A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)–HIV coinfection with high prevalence of tenofovir–based antiretroviral therapy use. <i>HIV Medicine</i> , 2023, 24, 55-74.	1.0	2
3	HBV transcription and translation persist despite viral suppression in HBV–HIV coinfected patients on antiretroviral therapy. <i>Hepatology</i> , 2023, 77, 594-605.	3.6	2
4	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 676-688.	1.1	4
5	Reply. <i>Hepatology</i> , 2022, 75, 761-763.	3.6	0
6	Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 8-25.	1.9	12
7	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 618-619.	1.9	0
8	Review article: hepatitis B—current and emerging therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 805-819.	1.9	13
9	Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. <i>Hepatology</i> , 2022, 76, 775-787.	3.6	7
10	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3275-e3285.	2.9	15
11	Enhanced Screening for Hepatitis D in the USA: Overcoming the Δ Blues. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2483-2485.	1.1	7
12	Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. <i>Hepatology</i> , 2021, 74, 1088-1100.	3.6	58
13	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	3.6	23
14	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651.	3.6	11
15	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	0
16	Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021, 384, 541-549.	13.9	101
17	The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. <i>Hepatology</i> , 2021, 74, 2813-2823.	3.6	4
18	Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	18

#	ARTICLE	IF	CITATIONS
19	Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2021, 116, 1686-1697.	0.2	20
20	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. <i>GastroHep</i> , 2021, 3, 196-208.	0.3	1
21	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1042-1056.	1.0	5
22	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV/HIV Co-infected Adults in North America. <i>Hepatology</i> , 2021, 74, 1174-1189.	3.6	11
23	Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response. <i>Hepatology Communications</i> , 2021, 5, 1888-1900.	2.0	3
24	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1526-1538.	1.0	6
25	Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. <i>Hepatology</i> , 2021, 74, 2395-2409.	3.6	36
26	Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection. <i>Hepatology</i> , 2021, 74, 3552-3553.	3.6	1
27	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults. <i>Hepatology</i> , 2020, 71, 411-421.	3.6	23
28	Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 700-709.e3.	2.4	44
29	Hepatitis B and C virus infection and risk of haematological malignancies. <i>Journal of Viral Hepatitis</i> , 2020, 27, 4-12.	1.0	9
30	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL/AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
31	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020, 4, 8-20.	2.0	43
32	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
33	Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Hepatology</i> , 2020, 71, 686-721.	3.6	526
34	Hepatic Histology in Treatment-naïve Children With Chronic Hepatitis B Infection Living in the United States and Canada. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 99-105.	0.9	6
35	Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America. <i>Annals of Hepatology</i> , 2020, 19, 437-445.	0.6	6
36	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 406-417.	3.7	64

#	ARTICLE	IF	CITATIONS
37	Hepatitis B. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 215-238.	1.0	36
38	Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 69, 2338-2348.	3.6	37
39	WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV. <i>Clinics in Liver Disease</i> , 2019, 23, 417-432.	1.0	36
40	Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years. <i>Antiviral Research</i> , 2019, 168, 61-67.	1.9	3
41	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 856-865.	1.0	17
42	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2541-2551.e2.	2.4	28
43	Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. <i>American Journal of Gastroenterology</i> , 2019, 114, 1753-1763.	0.2	17
44	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 746-757.	0.2	33
45	Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. <i>Journal of Clinical Investigation</i> , 2019, 130, 507-522.	3.9	74
46	Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy. <i>Hepatology</i> , 2018, 68, 2078-2088.	3.6	38
47	Hepatitis C Guidance 2018 Update: AASLD-IDSAS Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1477-1492.	2.9	509
48	EASL International Recognition Award Recipient 2018: Prof. Anna Lok. <i>Journal of Hepatology</i> , 2018, 68, 881-882.	1.8	0
49	Disease Pathways and Mechanisms of Potential Drug Targets. <i>Clinical Liver Disease</i> , 2018, 12, 12-18.	1.0	4
50	Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN- $\gamma$ . <i>Gut</i> , 2017, 66, 724-735.	6.1	55
51	Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. <i>Genetics in Medicine</i> , 2017, 19, 160-168.	1.1	124
52	Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 744-753.	1.9	54
53	Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 299-309.	1.0	54
54	Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1032-1042.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , 2017, 186, 356-366.	1.6	15
56	Determination of hepatitis B phenotype using biochemical and serological markers. <i>Journal of Viral Hepatitis</i> , 2017, 24, 320-329.	1.0	55
57	NAM 2017 report: A national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD's response. <i>Hepatology</i> , 2017, 66, 1020-1022.	3.6	9
58	Hepatitis B cure: From discovery to regulatory approval. <i>Journal of Hepatology</i> , 2017, 67, 847-861.	1.8	189
59	Hepatitis B cure: From discovery to regulatory approval. <i>Hepatology</i> , 2017, 66, 1296-1313.	3.6	235
60	Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. <i>Gastroenterology</i> , 2017, 153, 1392-1403.e2.	0.6	87
61	Cellular microRNA networks regulate host dependency of hepatitis C virus infection. <i>Nature Communications</i> , 2017, 8, 1789.	5.8	70
62	Long-term lamivudine therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 380-389.	1.9	14
63	Hepatitis E Virus Does Not Contribute to Hepatic Decompensation Among Patients With Advanced Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 896-902.	2.4	8
64	Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	0.6	178
65	Natural History of Chronic Hepatitis C. , 2016, , 3-55.		2
66	Should Family Physicians Routinely Screen Patients for Hepatitis C? Yes: Screening Makes Sense for High-Risk Adults. <i>American Family Physician</i> , 2016, 93, 15-6.	0.1	0
67	Hepatitis C guidance: AASLD&#x2013;IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. <i>Hepatology</i> , 2015, 62, 932-954.	3.6	1,139
68	Screening for hepatitis B virus to prevent viral reactivation &#x201c; who and when?. <i>Clinical Liver Disease</i> , 2015, 5, 47-50.	1.0	6
69	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908.	3.6	269
70	Diabetes and prediabetes in patients with hepatitis B residing in North America. <i>Hepatology</i> , 2015, 62, 1364-1374.	3.6	29
71	A Cure for the High Cost of Hepatitis C Virus Treatment. <i>Annals of Internal Medicine</i> , 2015, 162, 660-661.	2.0	12
72	Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. <i>Gastroenterology</i> , 2015, 149, 190-200.e2.	0.6	222

#	ARTICLE	IF	CITATIONS
73	The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus. JAMA Internal Medicine, 2015, 175, 169.	2.6	10
74	An Epidemiologic Investigation of a Case of Acute Hepatitis E. Journal of Clinical Microbiology, 2015, 53, 3547-3552.	1.8	11
75	Natural History of Hepatitis C. Gastroenterology Clinics of North America, 2015, 44, 717-734.	1.0	177
76	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192.	2.4	90
77	Durability of Antibody Response Against Hepatitis B Virus in Healthcare Workers Vaccinated as Adults. Clinical Infectious Diseases, 2015, 60, 505-513.	2.9	55
78	Building Bridges and Providing Transparency to the Hepatitis C Virus Drug Approval Process. Gastroenterology, 2014, 147, 1201-1203.	0.6	0
79	Long-term therapy of chronic delta hepatitis with peginterferon alfa. Alimentary Pharmacology and Therapeutics, 2014, 40, 93-104.	1.9	90
80	Reply. Hepatology, 2014, 59, 1651-1651.	3.6	1
81	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut, 2014, 63, 161-169.	6.1	51
82	Therapy of Hepatitis C " Back to the Future. New England Journal of Medicine, 2014, 370, 2043-2047.	13.9	102
83	QUEST for a cure for hepatitis C virus: the end is in sight. Lancet, The, 2014, 384, 381-383.	6.3	7
84	HARVEY ALTER AND MICHAEL HOUGHTON: THE DISCOVERY OF HEPATITIS C AND THE INTRODUCTION OF SCREENING TO PREVENT ITS TRANSMISSION IN TRANSFUSED BLOOD. , 2014, , 197-214.		1
85	Spontaneous Mutations in the HBV Genome and their Clinical Implications. Current Hepatitis Reports, 2013, 12, 79-87.	0.3	3
86	The Hepatitis B Vaccine Protects Re-Exposed Health Care Workers, But Does Not Provide Sterilizing Immunity. Gastroenterology, 2013, 145, 1026-1034.	0.6	47
87	Hepatitis B virus treatment: Management of antiviral drug resistance. Clinical Liver Disease, 2013, 2, 24-28.	1.0	7
88	Hepatitis E: The nonendemic perspective. Clinical Liver Disease, 2013, 2, 245-249.	1.0	1
89	Discordance Among Transient Elastography, Aspartate Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 303-308.e1.	2.4	29
90	The liver diseases of lipodystrophy: The long-term effect of leptin treatment. Journal of Hepatology, 2013, 59, 131-137.	1.8	138

#	ARTICLE	IF	CITATIONS
91	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894.	1.9	44
92	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. <i>Hepatology</i> , 2013, 58, 1548-1557.	3.6	96
93	Acute hepatitis C: to treat or not to treat. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 467-468.	4.6	3
94	Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1907-1917.	13.9	418
95	What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 56, 1629-1636.	2.9	23
96	Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 369, 679-680.	13.9	45
97	Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. <i>American Journal of Gastroenterology</i> , 2012, 107, 1388-1398.	0.2	14
98	A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors. <i>Journal of Infectious Diseases</i> , 2012, 206, 654-661.	1.9	28
99	The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. <i>Antiviral Chemistry and Chemotherapy</i> , 2012, 23, 1-12.	0.3	109
100	Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2423-2429.	1.1	106
101	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1027-1035.	1.9	19
102	The new standard of HCV therapy: Retreatment in experienced patients. <i>Clinical Liver Disease</i> , 2012, 1, 16-19.	1.0	0
103	Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1317-1325.	1.9	135
104	S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders. <i>Gastroenterology</i> , 2011, 140, 830-839.e3.	0.6	51
105	Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 840-849.e1.	0.6	178
106	Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. <i>Hepatology</i> , 2011, 53, 1100-1108.	3.6	55
107	A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2011, 54, 396-405.	3.6	142
108	Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2011, 54, 1527-1537.	3.6	27

#	ARTICLE	IF	CITATIONS
109	An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2011, 54, 1433-1444.	3.6	961
110	Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 884-893.	0.2	16
111	Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2010, 51, 585-594.	3.6	155
112	Outcome of sustained virological responders with histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 833-844.	3.6	428
113	Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 719-734.	1.9	22
114	Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1018-1027.	1.9	8
115	Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. <i>Journal of Viral Hepatitis</i> , 2010, 17, 59-64.	1.0	18
116	Editorial : Treatment of Patients With HCV-Related Cirrhosis With Peginterferon and Ribavirin: Swinging the Pendulum Toward Treatment. <i>American Journal of Gastroenterology</i> , 2010, 105, 2174-2176.	0.2	5
117	Management of Untreated and Nonresponder Patients with Chronic Hepatitis C. <i>Seminars in Liver Disease</i> , 2010, 30, 348-360.	1.8	7
118	Hepatitis B Virology for Clinicians. <i>Clinics in Liver Disease</i> , 2010, 14, 397-408.	1.0	17
119	Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 649-658.	1.0	24
120	Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alpha-Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 325-335.e2.	0.6	243
121	Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 136-146.	0.6	82
122	Factors That Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 2321-2331.e2.	0.6	38
123	Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. <i>Gastroenterology</i> , 2010, 139, 154-162.e4.	0.6	108
124	Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 877-883.	2.4	385
125	Diagnosis, management, and treatment of hepatitis C: An update. <i>Hepatology</i> , 2009, 49, 1335-1374.	3.6	2,610
126	Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. <i>Hepatology</i> , 2009, 49, 1828-1837.	3.6	51



#	ARTICLE	IF	CITATIONS
127	Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2009, 49, 1847-1858.	3.6	75
128	Antiviral resistance and hepatitis B therapy. <i>Hepatology</i> , 2009, 49, S174-S184.	3.6	189
129	Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. <i>Hepatology</i> , 2009, 50, 34-45.	3.6	44
130	Reply:. <i>Hepatology</i> , 2009, 50, 324-325.	3.6	3
131	Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 1360-1369.	3.6	153
132	Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. <i>Hepatology</i> , 2009, 50, 1738-1749.	3.6	60
133	Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. <i>Gastroenterology</i> , 2009, 136, 138-148.	0.6	570
134	Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. <i>Gastroenterology</i> , 2009, 137, 549-557.	0.6	125
135	Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. <i>Gastroenterology</i> , 2009, 137, 1986-1994.	0.6	31
136	Management of Antiviral Resistance in Chronic Hepatitis B. , 2009, , 273-287.		0
137	Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. <i>Hepatology</i> , 2008, 47, 605-612.	3.6	114
138	Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. <i>Hepatology</i> , 2008, 48, 1412-1419.	3.6	23
139	DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. <i>Journal of Hepatology</i> , 2008, 49, 548-556.	1.8	43
140	Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 234-241.	2.4	26
141	Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. <i>New England Journal of Medicine</i> , 2008, 359, 2429-2441.	13.9	445
142	Association between Body Mass Index and Diabetes and Hepatocellular Carcinoma. <i>Annals of Internal Medicine</i> , 2008, 148, 166.	2.0	2
143	Evolution of Therapy for Chronic Hepatitis B: Progressing from the Simple to the Complex. <i>Annals of Internal Medicine</i> , 2007, 147, 806.	2.0	5
144	Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. <i>Journal of Hepatology</i> , 2007, 46, 420-431.	1.8	125

#	ARTICLE	IF	CITATIONS
145	Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 245-254.	2.4	46
146	Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 103-112.	0.6	200
147	Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 132, 1574-1585.	0.6	154
148	Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy. <i>Gastroenterology</i> , 2007, 132, 1757-1766.	0.6	105
149	Two Cases of Thyroid Storm-Associated Cholestatic Jaundice. <i>Endocrine Practice</i> , 2007, 13, 476-480.	1.1	48
150	Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. <i>Hepatology</i> , 2007, 46, 74-83.	3.6	11
151	The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2007, 46, 424-429.	3.6	227
152	Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. <i>Hepatology</i> , 2007, 46, 254-265.	3.6	418
153	Efforts to Define the Natural History of Chronic Hepatitis C Continue. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1190-1192.	2.4	5
154	Assessment and Management of Chronic Hepatitis B. <i>Infectious Disease Clinics of North America</i> , 2006, 20, 63-79.	1.9	8
155	Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1048-1052.	2.4	90
156	Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2006, 131, 1440-1451.	0.6	83
157	The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 855-864.	0.5	94
158	Natural history of hbeag-negative chronic Hepatitis b. <i>Current Hepatitis Reports</i> , 2006, 5, 27-32.	0.3	0
159	Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. <i>Hepatology</i> , 2006, 43, 780-787.	3.6	70
160	HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. <i>Hepatology</i> , 2006, 44, 360-367.	3.6	46
161	Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. <i>Hepatology</i> , 2006, 44, 925-935.	3.6	53
162	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. <i>Hepatology</i> , 2006, 44, 1675-1684.	3.6	145

#	ARTICLE	IF	CITATIONS
163	Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. American Journal of Gastroenterology, 2006, 101, 983-992.	0.2	61
164	Pushing the treatment envelope for chronic hepatitis C? is more necessarily better?. Hepatology, 2005, 41, 234-236.	3.6	6
165	Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology, 2005, 41, 753-760.	3.6	210
166	Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology, 2005, 42, 282-292.	3.6	299
167	Assessment of liver fibrosis: Palpate, poke or pulse?. Hepatology, 2005, 42, 759-761.	3.6	19
168	Pilot study of interferon gamma for chronic hepatitis C. Journal of Hepatology, 2005, 43, 67-71.	1.8	32
169	Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. Journal of Hepatology, 2005, 43, 434-441.	1.8	310
170	Expression of Chemokine and Inhibitory Receptors on Natural Killer Cells: Effect of Immune Activation and HIV Viremia. Journal of Infectious Diseases, 2004, 189, 1193-1198.	1.9	75
171	Cellular Immune Responses to the Hepatitis B Virus Polymerase. Journal of Immunology, 2004, 173, 5863-5871.	0.4	86
172	Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Contemporary Clinical Trials, 2004, 25, 472-492.	2.0	160
173	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004, 39, 188-196.	3.6	679
174	Management of chronic hepatitis B. Gastroenterology Clinics of North America, 2004, 33, 563-579.	1.0	2
175	Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3]. Gastroenterology, 2004, 126, 1015-1023.	0.6	436
176	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38, 66-74.	3.6	83
177	E1 therapeutic vaccination for chronic hepatitis C: All that glitters is not gold. Hepatology, 2003, 38, 1092-1094.	3.6	1
178	A rapid immunochromatographic assay for hepatitis B virus screening. Journal of Viral Hepatitis, 2003, 10, 331-334.	1.0	28
179	Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124, 97-104.	0.6	368
180	Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology, 2003, 124, 352-360.	0.6	124

#	ARTICLE	IF	CITATIONS
181	Hepatitis B e Antigen " The Dangerous Endgame of Hepatitis B. New England Journal of Medicine, 2002, 347, 208-210.	13.9	31
182	Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology, 2002, 36, 1273-1279.	3.6	182
183	Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. American Journal of Gastroenterology, 2001, 96, 2968-2972.	0.2	66
184	Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. Journal of Viral Hepatitis, 2001, 8, 256-263.	1.0	42
185	16 Hepatitis C virus and human immunodeficiency virus coinfection. Biomedical Research Reports, 2000, 2, 315-328.	0.3	0
186	Long-Term Therapy of Chronic Hepatitis B With Lamivudine. Hepatology, 2000, 32, 828-834.	3.6	326
187	Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology, 1998, 27, 213-222.	3.6	324
188	10-year follow-up after interferon-? therapy for chronic hepatitis C. Hepatology, 1998, 28, 1121-1127.	3.6	275
189	Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. Journal of Viral Hepatitis, 1998, 5, 171-178.	1.0	39
190	Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection. Digestive Diseases and Sciences, 1996, 41, 2213-2218.	1.1	24
191	Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Digestive Diseases and Sciences, 1996, 41, 1265-1272.	1.1	64
192	A young woman with cirrhosis: Autoimmune hepatitis vs. $\alpha$ 1-antitrypsin deficiency. Hepatology, 1994, 19, 1302-1306.	3.6	4
193	Acute Viral Hepatitis. , 0, , 2073-2111.		0